CKD-702 + irinotecan

CKD-702 + irinotecan is a combination therapy being investigated for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma. This combination specifically targets patients whose tumors overexpress EGFR or MET proteins and is being studied as a third-line or later therapy option. CKD-702 is a tetravalent bispecific antibody that simultaneously targets two important receptors: - Epidermal growth factor receptor (EGFR) - Hepatocyte growth factor receptor (MET) The combination with irinotecan, a topoisomerase inhibitor chemotherapy agent, is being tested to potentially enhance efficacy in treating advanced gastric cancers that have failed previous treatment lines.